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Abstract
A	 key	 component	 of	 cardiac	 ischemia–reperfusion	 injury	 (IRI)	 is	 the	 increased	 gen-
eration	of	reactive	oxygen	species,	leading	to	enhanced	inflammation	and	tissue	dys-
function	in	patients	following	intervention	for	myocardial	infarction.	In	this	study,	we	
hypothesized	that	oxidative	stress,	due	to	ischemia–reperfusion,	induces	senescence	
which	contributes	to	the	pathophysiology	of	cardiac	IRI.	We	demonstrate	that	IRI	in-
duces cellular senescence in both cardiomyocytes and interstitial cell populations and 
treatment	with	the	senolytic	drug	navitoclax	after	ischemia–reperfusion	improves	left	
ventricular	 function,	 increases	 myocardial	 vascularization,	 and	 decreases	 scar	 size.	
SWATH-MS-based	proteomics	revealed	that	biological	processes	associated	with	fi-
brosis	and	inflammation	that	were	increased	following	ischemia–reperfusion	were	at-
tenuated	upon	senescent	cell	clearance.	Furthermore,	navitoclax	treatment	reduced	
the	expression	of	pro-inflammatory,	profibrotic,	and	anti-angiogenic	cytokines,	includ-
ing	interferon	gamma-induced	protein-10,	TGF-β3,	interleukin-11,	interleukin-16,	and	
fractalkine. Our study provides proof-of-concept evidence that cellular senescence 
contributes to impaired heart function and adverse remodeling following cardiac is-
chemia–reperfusion.	We	also	establish	that	post-IRI	the	SASP	plays	a	considerable	role	
in	the	inflammatory	response.	Subsequently,	senolytic	treatment,	at	a	clinically	feasible	
time-point,	attenuates	multiple	components	of	this	response	and	 improves	clinically	
important	parameters.	Thus,	cellular	senescence	represents	a	potential	novel	thera-
peutic	avenue	to	improve	patient	outcomes	following	cardiac	ischemia–reperfusion.
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1  |  INTRODUC TION
Coronary	 heart	 disease	 (CHD)	 is	 the	 leading	 cause	 of	 death	 and	
disability	 in	 developed	 countries	 (Roger,	 2007).	 The	most	 serious	
manifestation	of	CHD	is	ST-segment	elevation	myocardial	infarction	
(STEMI),	which	is	caused	by	acute	blockage	of	a	coronary	artery	lead-
ing to myocardial ischemia and cardiac cell death. The most effective 
intervention is timely reperfusion of the myocardium via primary 
percutaneous	coronary	intervention	(Lonborg,	2015).	Although	early	
intervention	can	limit	acute	myocardial	infarction	(MI)	injury,	reper-
fusion	can	itself	induce	ischemia–reperfusion	injury	(IRI)	resulting	in	
adverse myocardial remodeling and an increased risk of progression 
to	heart	failure	(Mozaffarian	et	al.,	2016;	Velagaleti	et	al.,	2008).	This	
necessitates the need to pursue the use of additional therapies to ei-
ther	prevent	or	ameliorate	myocardial	IRI,	which	has	been	described	
as	a	neglected	therapeutic	target	(Hausenloy	&	Yellon,	2013).
Cellular senescence is defined as an irreversible cell-cycle arrest 
characterized	by	dramatic	alterations	in	gene	and	protein	expression	
and the production of the senescence-associated secretory pheno-
type	 (SASP)	 (Coppe	 et	 al.,	 2008).	 The	 SASP	 consists	 of	 a	 cocktail	
of	pro-inflammatory	cytokines,	chemokines,	matrix	proteases,	and	
growth factors that if unhindered can induce many of the biological 
processes associated with maladaptive cardiac remodeling. These 
include	attenuation	of	regeneration,	induction	of	fibrosis	and	cellu-
lar	hypertrophy	and	inflammation	(Coppe	et	al.,	2010).	Furthermore,	
the	SASP	can	induce	senescence	in	surrounding	healthy	cells	leading	
to	the	spreading	of	senescence	throughout	affected	tissues	(Acosta	
et	 al.,	 2013).	 Senescence	 can	 be	 induced	 by	 a	 variety	 of	 stresses	
including	oxidative	 stress	 (Anderson	 et	 al.,	 2018;	 de	Magalhaes	&	
Passos,	2018).
A	key	component	of	IRI	 is	the	increased	generation	of	reactive	
oxygen	 species	 (Chouchani	 et	 al.,	 2014)	which	 is	 thought	 to	 con-
tribute	 to	 tissue	dysfunction.	Previously,	we	have	shown	 that	car-
diomyocyte	 (CM)	 senescence	 can	 be	 induced	 by	 oxidative	 stress,	
accumulates	 during	 aging	 (Anderson	 et	 al.,	 2019;	 Walaszczyk	
et	al.,	2019),	and	contributes	to	age-related	myocardial	remodeling	
(Anderson	et	al.,	2019).	Furthermore,	using	the	senolytic	navitoclax	
(ABT263),	a	Bcl-2	family	inhibitor,	we	demonstrated	that	elimination	
of	 age-related	 senescence	 prior	 to	MI	 improved	 outcome	 in	 aged	
mice	(Walaszczyk	et	al.,	2019).	These	data	indicate	that	pre-existing	
senescence	 impairs	 recovery	 in	 aged	 animals;	 however,	 the	 possi-
bility that senescence is induced during IRI and contributes to the 
disease pathophysiology has not been investigated.
In	 this	 study,	 we	 hypothesized	 that	 cellular	 senescence	 is	 an	
outcome	of	 the	oxidative	burst	occurring	during	cardiac	 IRI	and	 is	
a key contributor to its associated adverse ventricular remodeling 
and	 impaired	 cardiac	 function.	 We	 show	 that	 cardiac	 ischemia–
reperfusion	 (IR)	 induces	myocardial	 senescence	 and	expression	of	
a	pro-inflammatory,	profibrotic,	and	anti-angiogenic	SASP	in	young	
adult	mice.	Post-IR,	treatment	with	navitoclax	clears	senescent	cells	
in	 the	 heart,	 attenuates	 SASP-mediated	 inflammation,	 increases	
myocardial	vascularization,	reduces	scar	size,	and	leads	to	improved	
cardiac function. Our work provides proof-of-concept that targeting 
senescent cells may represent a new therapeutic avenue following 
cardiac IR.
2  |  RESULTS
2.1  |  Myocardial infarction with reperfusion 
induces senescence in multiple cardiac lineages
To determine whether senescence is induced in a clinically relevant 
model	of	cardiac	IRI,	3-	to	4-month-old	male	mice	were	subjected	to	
60	minutes	LAD-ligation	followed	by	reperfusion	and	hearts	were	
collected	 at	 different	 time-points	 after	 reperfusion	 (Figure	 1A).	
The	qRT-PCR	analysis	 in	hearts	collected	at	4-weeks	post-IR	dem-
onstrated	 that	 mRNAs	 encoding	 senescence-associated	 markers	
p16 and p21 were increased in the myocardium of IR injured mice 
compared	to	controls	(Figure	1B).	Furthermore,	histological	analysis	
showed	an	increased	expression	of	senescent	markers	both	within	
the infarct and in the peri-infarct region of the left ventricular myo-
cardium	(Figure	1C–E	and	Figure	S1A).	At	72	hours,	cells	within	the	
infarct	 and	 the	 peri-infarct	 zone	 showed	 increased	 senescence-
associated β-galactosidase	activity	(SA-β-Gal)	(Figure	1C).	SA-β-Gal 
activity was also evident 1-week post-IR throughout the infarct in 
interstitial	 cells	and	CMs	 (Figure	1C	and	Figure	S1B).	 IRI	 is	associ-
ated	with	 increased	 oxidative	 stress	 (Peoples	 et	 al.,	 2019),	 and	 in	
line	with	 this,	we	 saw	 an	 increase	 in	 4-HNE	 staining	 (a	marker	 of	
lipid	peroxidation)	in	the	infarct	zone	at	72	hours	following	IR,	with	
the	 area	 demonstrating	 the	 highest	 levels	 of	 oxidative	 stress	 also	
displaying	the	highest	senescence	burden	(Figure	S2).	During	aging,	
senescence	in	CMs	is	characterized	by	the	presence	of	telomere-as-
sociated	DNA	damage	foci	(TAF)	which	can	be	induced	by	oxidative	
stress	(Anderson	et	al.,	2019).	To	ascertain	if	telomere	dysfunction	
occurred	in	CMs	following	IR,	we	quantified	TAF	in	CMs	within	the	
peri-infarct	region.	We	found	that	the	frequency	of	CMs	positive	for	
≥5	TAF	was	significantly	increased	in	IR	injured	mice	at	both	1	week	
(1.53%±0.45	 vs	 54.0%±8.3)	 and	 4	 weeks	 post-IR	 (17.71%±7.67)	
(Figure	1D).	Following	an	assessment	of	p16	antibody	specificity	(see	
Methods	and	Figure	S3	for	details),	we	found	a	significant	increase	
in	the	frequency	of	cells	expressing	p16	protein	4	weeks	following	
IR	compared	with	controls	(Figure	1E).	This	included	CMs,	identified	
via	co-expression	of	troponin	C	(trop-C),	and	cells	of	the	interstitial	
population.
2.2  |  Navitoclax eliminates senescent cells and 
improves cardiac function following cardiac ischemia–
reperfusion injury
To ascertain if the observed increase in senescence following car-
diac IR contributes to detrimental pathophysiology and represents 
a	 valid	 therapeutic	 target	 to	 improve	 outcome,	 we	 investigated	
the	effects	of	navitoclax	treatment.	At	4	days	post-IR,	once	senes-
cence	was	established,	mice	were	treated	with	either	vehicle	only	or	
    |  3 of 15DOOKUN et al.
navitoclax	for	7	consecutive	days	(Figure	2A).	Immunohistochemical	
analysis	of	the	LV	at	1	month	after	navitoclax	treatment	showed	a	
significant reduction in the proportion of p16+	CMs	(24.56%±2.45	vs	
6.60%±2.16)	and	p16+	interstitial	cells	(19.76%±1.82	vs	8.90%±2.66)	
in	the	peri-infarct	region	of	navitoclax-treated	compared	to	vehicle-
treated	hearts	(Figure	2B,C).	A	reduction	in	p21	expressing	CMs	in	
the	peri-infarct	region	(20.00%	±1.57	vs	7.12%	±0.94)	was	also	ob-
served	at	 the	same	 time-point	 (Figure	2D,E).	CMs	with	more	 than	
5	 TAF	 were	 also	 reduced	 in	 the	 peri-infarct	 region	 in	 navitoclax-
treated	 animals	 (14.22%	 ±2.34	 vs	 6.41%	 ±1.63).	 Having	 demon-
strated	 the	 effectiveness	 of	 navitoclax	 to	 reduce	 senescence,	 we	
next	 aimed	 to	determine	 if	 there	 is	 a	 causal	 relationship	between	
F I G U R E  1 Cardiac	ischemia–reperfusion	induces	cellular	senescence.	(a)	Experimental	design.	Mice	were	either	subjected	to	60	minutes	
LAD-ligation	followed	by	reperfusion	(IR)	or	received	no	injury	(Control)	and	hearts	collected	at	the	indicated	times.	(b)	At	4	weeks	post-
IR,	hearts	were	collected	and	the	LV	region	apical	to	suture	isolated.	Real-time	qPCR	gene	expression	analysis	performed	to	determine	the	
relative	expression	of	p16	and	p21	mRNA	(normalized	to	GADPH).	N	≥	4/group.	(c)	SA-β-Gal	staining	in	control	and	at	24	hours,	72	hours,	
and	1	week	post-IR.	Lower	panels)	Higher	magnification	images	of	the	peri-infarct	region.	Scale	bars	50	µm.	(d)	Representative	images	of	
TAF,	γH2AX	co-localized	with	Telomere	immuno-FISH,	in	a	trop-C+	CM	(trop-C	white,	telo-FISH	red,	γH2AX	green).	White	arrows	indicate	
individual	TAF.	Images	are	obtained	from	the	z-stacks	of	10	μm	sections.	Right	image	panel)	Higher	magnification	of	5	regions	showing	
6	individual	TAF.	The	merged	image	demonstrates	the	co-localization	of	γH2AX	(green)	and	telomere	(red).	Individual	red	and	green	
channels	are	also	shown.	Scale	bar	2.5	μm.	Right)	The	mean	number	of	CMs	with	≥5-TAF	at	1	and	4	weeks	post-IR.	N	=	3/group.	(e)	Left)	
Representative	image	of	p16	expression	at	4	weeks	post-IRI	(p16	red,	trop-C	green,	DAPI	blue.	(i)	shows	a	magnified	example	of	a	p16+	CM	
(trop-C+),	and	(ii)	is	an	example	of	a	p16+	interstitial	cell.	Scale	bar	20	µm.	Right)	Quantification	of	the	percentage	p16	expressing	cells	at	
4	weeks	post-IR	N	≥	3/group.	Data	are	mean	±	SEM.	B	and	E	were	analyzed	by	2-tailed	unpaired	t-test;	D	was	analyzed	by	a	1-way	ANOVA	
followed	by	Tukey's	post	hoc	test,	**p	<	0.01;	*p < 0.05
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senescence and impaired cardiac function following IR. In a separate 
cohort	of	mice,	 cardiac	MRI	was	performed	at	5	weeks	post-IR	 in	
navitoclax	and	vehicle-treated	mice.	All	 ligated	mice	demonstrated	
increased	LV	end-systolic	volumes	(ESV)	and	a	decrease	in	ejection	
fraction	(EF)	(Figure	2F–H).	Mice	treated	with	navitoclax	showed	a	
significantly	higher	EF	than	vehicle	controls	 (Figure	2G)	as	a	result	
of	a	better	maintained	LV	systolic	volume	 (Figure	2H).	 In	addition,	
navitoclax-treated	mice	displayed	a	significantly	larger	cardiac	out-
put	and	stroke	volume	compared	 to	 the	vehicle	group	 (Figure	S5).	
No	significant	difference	in	EDV	was	observed	between	any	experi-
mental	group	(Figure	2H).	These	data	support	a	role	for	senescence	
driven myocardial dysfunction following cardiac IR.
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2.3  |  Proteome profiling indicates that 
modulation of molecular pathways involved in 
remodeling, inflammation, and respiration underlies 
navitoclax-mediated improvement in cardiac function 
post-IR
We	 next	 conducted	 proteomic	 profiling	 to	 identify	 the	 protein	
networks modified by IR as well as the protein networks that are 
modified by senescence clearance at 7 days post-IR. This early time-
point was chosen to allow the identification of those networks that 
may contribute to the observed improvement in cardiac function 
rather than protein networks that are modified as a result of the 
observed	improvement	 (Figure	3A).	At	this	time-point,	a	reduction	
in	p21	expression	was	observed	in	the	LV	of	navitoclax-treated	ani-
mals	compared	to	vehicle	controls,	consistent	with	the	elimination	
of	 senescence	 (Figure	 S6).	 Having	 demonstrated	 that	 navitoclax	
was	reducing	senescence	by	day	7	post-IR,	LC-MS/MS	analysis	was	
performed	on	protein	 lysates	obtained	from	LV	tissue	posterior	to	
the	suture	(containing	the	infarct	and	surviving	myocardium	within	
this	region	of	the	LV)	of	vehicle	control	and	navitoclax-treated	mice	
at	 7	 days	 post-IR	 and	 comparable	 regions	 of	 LV	 from	 naïve,	 age-
matched	 control	 mice	 (Figure	 3B).	 From	 a	 total	 of	 3213	 proteins	
quantified	in	these	LV	tissues,	162	were	increased	(T-test,	FDR<0.05)	
and 142 were reduced following IR. To identify the proteins/path-
ways	modulated	by	navitoclax	selected	protein	abundance	profiles	
were	analyzed	 to	 identify	proteins	 increased	by	 IR	but	attenuated	
following	 navitoclax	 treatment	 (profile1)	 (Figure	 3C).	 137	 proteins	
were identified that followed this profile at an FDR <0.01 and 376 
at	an	FDR	of	<0.05	(Data	set	1).	To	assess	the	potential	significance	
of	these	proteins	to	biological	functions,	pathway	analysis	was	per-
formed	in	string	V	11.0,	(Szklarczyk	et	al.,	2019)	for	the	137	proteins	
matching	 the	 reference	with	 FDR	<0.01	 (Figure	 S7).	 Enriched	GO	
terms	(biological	processes)	included	processes	related	to	inflamma-
tion,	such	as	secretion	by	cell,	cellular	secretion,	immune	response,	
and	response	to	cytokine	(Figure	3D).	Additionally,	the	analysis	indi-
cated	that	navitoclax	treatment	attenuated	proteins	involved	in	bio-
logical	 processes	 related	 to	 supramolecular	 fiber	 organization	 and	
cytoskeleton	organization.
Next,	 we	 aimed	 to	 identify	 the	 proteins/pathways	 that	 fol-
lowed	profile	2	 (decreased	by	 IR	and	 rescued	 following	navitoclax	
treatment)	(Figure	3E)	and	identified	199	proteins	that	followed	this	
profile	at	an	FDR	<0.01	and	527	at	an	FDR	of	<0.05	 (Data	Set	2).	
Pathway	analysis	of	the	199	proteins	with	an	FDR	<0.01	(Figure	S8),	
identified GO terms enriched for this profile were related to cellular 
respiration	 and	 mitochondrial	 function	 including,	 oxidative	 phos-
phorylation	and	the	electron	transport	chain	(Figure	3F),	suggesting	
that	 navitoclax	 treatment	 may	 improve	 in	 mitochondrial	 function	
and	attenuate	the	oxidative	stress	caused	by	 IR.	Examples	of	pro-
tein	networks	for	the	GO	term	“immune	response,”	enriched	in	the	
proteins	following	profile	1	and	“cellular	respiration,”	enriched	in	the	
proteins	following	profile	2,	are	shown	in	Figure	3G.
2.4  |  Navitoclax attenuates the SASP
Pathway analysis of the proteomics data indicated a reduction of se-
nescence resulted in the modulation of multiple protein networks 
associated	with	inflammation	and	cytokine	activity.	As	such,	it	is	at-
tractive	 to	 hypothesize	 that	 elimination	of	 senescent	 cells	 post-IR	
improves outcome as a result of attenuation of a pro-inflammatory 
and	profibrotic	SASP.	To	investigate	this	further	a	cytokine	array	was	
used	to	evaluate	cytokines	released	within	the	LV	of	naïve	control	
and	 IR	 hearts	 treated	with	 either	 vehicle	 or	 navitoclax	 harvested	
at	7	days	post-injury,	as	in	(Figure	3A).	As	previously,	proteins	were	
isolated	 from	 the	 LV	 tissue	 posterior	 to	 the	 suture	 (containing	 all	
the	infarct	and	surviving	myocardium)	from	vehicle	and	navitoclax-
treated	 IR	 and	 control	mice	 to	 compare	 cytokine	 expression.	 The	
analysis	revealed	that	IR	caused	an	up-regulation	of	SASP	proteins	
including	interleukin-6	(IL-6),	interferon	gamma-induced	protein	10	
(IP-10),	eotaxin,	and	members	of	the	TGF-β	superfamily.	Importantly,	
these	SASP	proteins	were	reduced	in	the	navitoclax-treated	IR	ani-
mals	(Figure	4A,B).	In	addition,	interleukin-11	(IL-11),	interleukin-16	
(IL-16),	CCL22,	and	MIP-3β which have been previously associated 
with	 cardiac	 fibrosis,	 (Schafer	 et	 al.,	 2017;	 Tamaki	 et	 al.,	 2013)	 or	
cardiovascular	disease	 (Kimura	et	 al.,	 2018;	Safa	et	 al.,	 2016),	 and	
fractalkine	 (CX3CL1),	 a	 chemokine	 associated	with	 poorer	 cardiac	
functional	 outcome	 and	 increased	 mortality	 in	MI	 patients	 (Boag	
et	al.,	2015),	showed	a	similar	trend	of	reduction	following	navitoclax	
treatment.	A	complete	list	of	cytokines	and	their	expression	levels	is	
included in Supplementary Table I.
F I G U R E  2 Pharmacological	clearance	of	senescent	cells	following	ischemia–reperfusion	reduces	cellular	senescence	and	improves	
cardiac	function.	(a)	Mice	were	either	subjected	to	60-minute	IR	or	received	no	injury	(Control).	After	IR	mice	were	randomly	assigned	
to	the	vehicle	(IR)	or	navitoclax	(IR+Nav)	groups	and	provided	with	navitoclax	or	vehicle	daily	from	4	days	post-IR	for	7	days.	MRI	was	
performed	at	5	weeks	post-IR,	and	hearts	were	collected.	(b)	Representative	images	of	trop-C+	CMs	co-expressing	p16	(examples	indicated	
by	white	arrows)	and	p16	expressing	intestinal	cells	(examples	indicated	by	yellow	arrows)	in	the	LV	peri-infarct	region	(p16	red,	trop-C	
green	and	DAPI	blue).	Scale	bars	20	µm.	(c)	Quantification	of	the	percentage	trop-C+	CMs	and	intestinal	cells	expressing	p16+	in	the	LV	
peri-infarct	region.	N	≥	3/group.	(d)	Representative	images	of	trop-C+	CMs	co-expressing	p21	in	the	LV	peri-infarct	region	(p21	red,	trop-C	
green,	and	DAPI	blue).	White	arrows	indicate	examples	of	p16+	CMs.	Scale	bars	20	µm.	(e)	Quantification	of	the	percentage	of	trop-C+ 
CMs	co-expressing	p21+	in	the	LV	peri-infarct	region.	N	=	3/group.	(f)	Examples	of	individual	short-axis	cine-MR	images	of	mouse	hearts.	
Scale	bars	5	mm.	G	and	(h)	EF%,	EDV	and	ESV	were	calculated	based	on	manual	measurements	of	LV	epicardial	and	endocardial	borders.	
Measurements	were	made	in	all	cine	slices	at	end-diastole	and	end-systole.	Graphs	representing	data	obtained	from	MRI	analysis.	Control	
N	=	6,	IR	N	=	12	and	IR+Nav	N	=	13.	Data	are	mean±SEM.	c,	e,	g,	and	H	were	analyzed	by	one-way	ANOVA	followed	by	Tukey's	post	hoc	
test,	**p	<	0.01;	*p < 0.05
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2.5  |  Navitoclax treatment reduces infarct size and 
promotes angiogenesis but not cardiomyocyte 
proliferation in vivo
Navitoclax	treatment	post-IR	reduces	expression	of	SASP	proteins	
with established roles in myocardial remodeling and attenuates 
biological	pathways	 related	 to	 inflammation,	ECM	production,	and	
cytoskeletal	organization.	These	findings	led	us	to	hypothesize	that	
the	elimination	of	senescence	and	its	associated	SASP	leads	to	im-
proved cardiac recovery via a reduction in adverse myocardial re-
modeling.	Mice	were	 treated	as	previously	and	also	provided	EdU	
to	allow	quantification	of	proliferation	(Figure	5A).	 In	 line	with	our	
F I G U R E  3 Proteomic	pathway	profiling	demonstrates	navitoclax	modulates	protein	networks	involved	in	remodeling,	inflammation,	
and	respiration.	(a)	Experimental	design.	Mice	were	either	subjected	to	60-minute	IR	or	received	no	injury	(Control).	After	IR	mice	were	
randomly	assigned	to	the	vehicle	(IR)	or	navitoclax	(IR+Nav)	groups	and	provided	with	navitoclax	or	vehicle	daily	from	4	days	post-IR	for	
4	days.	On	the	fourth	day	of	treatment,	hearts	were	collected	and	the	LV	apical	to	the	suture	isolated	for	analysis	(N	=	3/group).	For	control	
mice,	a	comparable	region	of	LV	was	isolated	for	the	analysis.	(N	=	3).	(b)	Workflow	for	SWATH-MS	proteomics.	(c)	Perseus	software	was	
used	to	identify	proteins	that	followed	Profile	1.	Vertical	lines	represent	biological	repeats	in	each	of	the	indicated	groups.	Horizontal	lines	
indicate	individual	proteins	that	followed	the	profile	at	an	FDR	<	0.01.	(d)	List	of	selected	significantly	enriched	GO	biological	terms	for	the	
proteins	identified	to	follow	profile	1	at	an	FDR	<	0.01.	(e)	Perseus	software	was	used	to	identify	proteins	that	followed	Profile	2.	Vertical	
lines	represent	biological	repeats	in	each	of	the	indicated	groups.	Horizontal	lines	indicate	individual	proteins	that	followed	the	profile	at	an	
FDR	<	0.01.	(f)	List	of	selected	significantly	enriched	GO	biological	terms	for	the	proteins	identified	to	follow	profile	2	at	an	FDR	<	0.01.	(g)	
Examples	of	enriched	protein	networks	for	the	GO	term	“immune	response,”	which	followed	profile	1	(increased	following	IR	and	attenuated	
by	navitoclax	treatment),	and	the	GO	term	“cellular	respiration”	which	followed	profile	2	(decreased	following	IR	and	rescued	by	navitoclax	
treatment)
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hypothesis,	scar	size	measured	by	Masson's	trichrome	staining	was	
significantly	 reduced	 in	 the	 navitoclax-treated	 mice	 compared	 to	
vehicle control at 5 weeks post-IR (12.47%±1.68	 vs	 18.50%±2.72	
Figure	5B).	IR	also	resulted	in	a	significant	increase	in	CM	size;	how-
ever,	 no	 difference	was	 observed	 between	 the	 navitoclax-treated	
and	 vehicle	 groups	 (Figure	 5C).	 Accumulation	 of	 senescence	 and	
expression	of	 the	SASP	could	also	 impact	on	 regeneration	via	 the	
bystander effect. To investigate de novo	CM	regeneration	following	
navitoclax	treatment	we	quantified	EdU	positive	cells	in	combination	
with	the	CM	marker	trop-C	and	cell	membrane	marker	wheat	germ	
agglutinin	(WGA)	in	the	peri-infarct	region	of	the	myocardium.	We	
found	a	trend	toward	an	increase	in	EdU	labeled	CMs	following	navi-
toclax;	however,	this	was	not	significant	(0.91	±	0.30	cells	per	FOV	
vs	0.72	±	0.14	cells	per	FOV,	Figure	5D).
Proteomic data analysis also indicated that the elimination of 
senescent	cells	and	the	SASP	 is	associated	with	 improved	respira-
tion. This together with the documented anti-angiogenic activities 
of	SASP	proteins,	including	IP-10	(Campanella	et	al.,	2010),	led	us	to	
further	hypothesize	that	subsequent	to	IR	SASP	inhibits	endothelial	
proliferation	leading	to	reduced	angiogenesis.	Accordingly,	a	navito-
clax-mediated	reduction	 in	senescence	and	SASP	would	attenuate	
this effect and allow for increased angiogenesis. Histological analysis 
of	 EdU	 together	with	 the	 endothelial	 cell	marker	CD31	 showed	 a	
significant increase in endothelial cell proliferation in the navito-
clax-treated	 animals	 compared	 with	 vehicle	 controls	 (7.62	 ±	 1.67	
cells	per	FOV	vs	4.11	±	1.3	cells	per	FOV,	Figure	5E).	To	establish	if	
this	could	be	a	result	of	SASP	driving	endothelial	cells	to	senescence,	
we performed in vitro	conditioned	media	experiments.	Conditioned	
medium isolated from senescent fibroblasts reduced cardiac en-
dothelial	 cell	 proliferation	 (measured	 by	 Ki67	 expression	 and	 cell	
output)	and	increased	endothelial	superoxide	production,	a	charac-
teristic	of	endothelial	cell	dysfunction	(Figure	S9).	Furthermore,	en-
dothelial cells treated with conditioned media from senescent cells 
demonstrated	 increased	 p21	but	 not	 p16	 expression	 (Figure	 S9F).	
Finally,	we	quantified	peri-infarct	region	vascularity.	Consistent	with	
an in vivo	pro-angiogenic	effect	(Redgrave	et	al.,	2017),	the	peri-in-
farct	region	of	hearts	from	animals	treated	with	navitoclax	had	sig-
nificantly	increased	vessel	density	in	the	peri-infarct	zone	compared	
vehicle	 control	 (14.38%±2.88%	 vs	 8.87%±1.74,	 Figure	 5F).	 Taken	
together,	our	data	 indicate	 that	 in	young	animals	cardiac	 IR	drives	
senescence	and	a	pro-inflammatory,	anti-angiogenic,	and	profibrotic	
SASP.	Moreover,	 navitoclax	mediates	 the	 reduction	 in	 senescence	
and	 improves	cardiac	 function	by	attenuating	SASP,	 reducing	 scar	
size,	and	enabling	increased	angiogenesis.
F I G U R E  4 Navitoclax	treatment	attenuates	the	post-ischemia–reperfusion	inflammatory	response.	(a)	Clustered	heatmap	showing	
all	analyzed	cytokine	protein	levels	in	the	LV	of	naïve	control	(Control)	and	IR	with	either	vehicle	(IR)	or	navitoclax	treatment	(IR	+Nav).	
(b)	Expression	of	individual	protein	levels	in	the	LV	myocardium	of	heart	in	the	indicated	experimental	groups.	Data	are	mean	±	SEM	for	each	
treatment	group.	N	=	3/group.	Analysis	for	all	proteins	was	by	one-way	ANOVA	followed	by	Tukey's	post	hoc	test,	*p	<	0.05,	**p < 0.01
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F I G U R E  5 Navitoclax	reduces	scar	size	and	increases	angiogenesis	but	has	no	influence	on	hypertrophy	or	cardiomyocyte	proliferation.	
(a)	Experimental	design.	Mice	were	subjected	to	60-minute	LAD-Ligation	with	reperfusion	and	then	at	day	4	post-IR	were	treated	with	
vehicle	(IR)	or	navitoclax	(IR	+Nav)	daily	for	7	days.	Mice	were	also	provided	with	EdU	during	the	same	period.	Hearts	were	collected	at	
5	weeks	post-IR.	(b)	Representative	image	of	Masson's	trichrome	staining.	Scale	bars	1	mm.	Right)	Quantification	of	infarct	size	relative	to	
total	LV	area.	N	=	7/group.	(c)	Representative	images	of	WGA	staining	for	quantification	CM	cross-sectional	area.	Scale	bars	50	µm	Right)	
CM	cross-sectional	area	μm2.	N	=	4/group,	>150	CMs	analyzed	per	mouse.	(d)	Representative	image	of	trop-C+	CMs	co-labeled	with	EdU	
highlighted	in	yellow	(Trop-C	green,	EdU	Red	and	WGA	white).	Scale	bars	20	µm	Right)	Quantification	of	trop-C+/EdU+ cells per field of view 
in	the	peri-infarct	region.	N	=	4/group.	(e)	Representative	image	of	CD31+	expressing	endothelial	cells	co-labeled	with	EdU	(trop-C	green,	
EdU	Red).	White	arrows	indicate	co-labeled	cells.	Scale	bars	20	µm.	Right)	Quantification	of	the	total	number	of	CD31+/EdU+ cells per field 
of	view	in	the	peri-infarct	region.	N	≥	4/group.	(f)	Vessel	density	in	the	peri-infarct	and	infarct	zone	analyzed	using	CD31	immunostaining.	
Scale	bars	50	µm.	Right)	Quantification	of	the	percentage	area	of	CD31	expression.	N	≥	4/group.	Data	are	mean	±	SEM;	b,	d,	e,	and	f	were	
analyzed	2-tailed	unpaired	t-test;	and	C	was	analyzed	by	one-way	ANOVA	followed	by	Tukey's	post	hoc	test,	***p	<	0.001;	**p < 0.01; 
*p < 0.05
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3  |  DISCUSSION
Efforts	to	target	the	oxidative	insult	that	occurs	immediately	follow-
ing	IR	using	therapies	such	as	antioxidants	have	proven	unsuccessful	
(Baehr	et	al.,	2019).	The	current	study	provides	novel	data	demon-
strating	that	navitoclax	mediates	elimination	of	the	senescence	that	
occurs	 downstream	 of	 oxidative	 stress	 and	 that	 this	 reduces	 scar	
size,	increases	angiogenesis,	and	improves	cardiac	function.
Subsequent	to	cardiac	IR,	the	degree	to	which	remodeling	occurs	
is not only dependent on the immediate detrimental processes asso-
ciated	with	 ischemia	and	rapid	oxidative	stress	due	to	 reperfusion	
but	is	also	dependent	on	the	outcomes	of	a	complex	inflammatory	
response	 (Sánchez-Hernández	et	al.,	2020).	Tissue	damage	caused	
by IR induces an acute inflammatory response responsible for the 
elimination	 of	 necrotic	 debris	 (Prabhu	 &	 Frangogiannis,	 2016).	 In	
mice,	 this	 initial	 response	begins	 to	abate	at	 around	5	days,	being	
replaced by a reparative and proliferative phase which functions 
to suppress the acute response and coordinates tissue remodeling 
(Sánchez-Hernández	et	al.,	2020).	While	both	phases	of	 inflamma-
tion	are	 required	 for	 successful	wound	healing	 they	can	also	con-
tribute to myocardial dysfunction. The acute inflammatory response 
can	 expand	 tissue	 damage	 and	 a	 severe	 or	 prolonged	 reparative	
response	is	associated	with	pathological	scarring	fibrosis	(Prabhu	&	
Frangogiannis,	2016).
Using	a	SWATH-MS	based	proteomic	approach	we	have	demon-
strated	 that	 navitoclax-mediated	 reduction	 of	 senescence	 results	
in the attenuation of multiple biological processes associated with 
inflammation	 and	 immunity.	 Furthermore,	 cytokine	 array	 analy-
sis	 identified	 that	 this	 attenuation	 included	 reduced	expression	of	
cytokines associated with the nuclear factor-κB	 (NF-κB)	 signaling	
pathway	including	CCL22,	IL-6,	IL-11,	IP-10,	eotaxin,	and	fractalkine	
(Bhavsar	et	al.,	2008;	Bitko	et	al.,	1997;	Hein	et	al.,	1997;	Nakayama	
et	al.,	2004;	Shultz	et	al.,	2007;	Son	et	al.,	2008).	These	proteins	are	
not	only	 typical	of	 the	SASP	 (Salminen	et	 al.,	 2012)	but	have	also	
been identified as modulators of the acute inflammatory phase fol-
lowing	IR	(Boag	et	al.,	2015).	Mouse	models	in	which	the	NF-κB sig-
naling	pathway	or	individual	NF-Κb-mediated proteins are reduced 
demonstrate	decreased	pathological	remodeling,	a	reduction	in	scar	
size	and	 improved	vascularization	 (Campanella	et	al.,	2010;	Obana	
et	al.,	2010;	Prabhu	&	Frangogiannis,	2016).	Conversely,	overexpres-
sion	of	NF-κB	associated	cytokines,	such	as	IL-6,	exhibit	adverse	re-
modeling	and	heightened	myocardial	inflammation	(Hilfiker-Kleiner	
et	al.,	2010).	Our	data	suggest	that	senescence	and	the	SASP	con-
tribute	directly	to	acute	inflammation	post-IR	and	senolytics,	such	as	
navitoclax,	provide	a	means	to	attenuate	the	production	of	multiple	
cytokines	and	chemokines,	known	to	be	detrimental	to	recovery.
As	senescence	was	evident	by	3	days	post-IR,	we	treated	mice	
from	this	time-point	using	a	dose	of	navitoclax	that	we	have	previ-
ously	shown	to	induce	myocardial	senolysis	(Anderson	et	al.,	2019).	
This	treatment	extended	into	the	reparative	phase	of	the	response	
to	 heart	 injury,	 a	 phase	 that	 is	 characterized	 by	 the	 secretion	 of	
TGF-β1,	 an	 anti-inflammatory	 and	 profibrotic	 cytokine	 (Hanna	
&	 Frangogiannis,	 2019).	 TGF-β	 expression	 is	 dynamic	 in	 the	 heart	
post-IR,	where	it	is	critical	for	the	switch	from	the	pro-inflammatory	
to	the	resolution	phase	of	cardiac	healing,	and	for	driving	formation	
of	the	fibrotic	scar.	In	mice,	TGF-β1 and β2	expression	peaks	at	6–72	
hours	post-reperfusion	and	declines	after	3	to	7	days	(Deten	et	al.,	
2001;	Dewald	et	al.,	2004).	TGF-β3	expression	is	induced	at	a	later	
3-7 day time-point and is maintained at high levels over a longer 
time-frame.	Early	neutralization	of	TGF-β	signaling	at	24	h	post-MI	
is	detrimental	as	it	increases	both	cardiac	dysfunction	and	mortality,	
whereas late disruption of TGF-β signaling is protective for fibrosis 
and	hypertrophic	remodeling	(Ikeuchi	et	al.,	2004).
Here,	we	demonstrate,	as	with	 the	aging	heart,	 there	 is	an	as-
sociation between the level of myocardial TGF-β	 ligand	expression	
and	the	level	of	myocardial	senescence.	It	is,	therefore,	possible	that	
the	SASP	also	contributes	to	driving	fibrosis	and	scar	formation;	a	
hypothesis	supported	by	the	reduced	scar	size	observed	in	the	nav-
itoclax-treated	 animals.	While	 our	 observations	 initially	 appear	 at	
odds	with	studies	demonstrating	that	senescence	is	required	to	at-
tenuate	cardiac	fibrosis	(Meyer	et	al.,	2016;	F.	L.	Zhu	et	al.,	2013),	it	
is	important	to	note	that	navitoclax	does	not	inhibit	senescence,	but	
induces	apoptosis	once	senescence	is	achieved	(Y.	Zhu	et	al.,	2015).	
Therefore,	 the	 two	 observations	 are	 entirely	 compatible.	 Indeed	
Zhu	et al propose that while fibroblast senescence reduces collagen 
deposition	in	the	short	term	post-MI,	senescent	fibroblasts	are	also	
a source of chronic inflammation contributing to ongoing cardiac fi-
brosis	in	the	longer	term	(F.	L.	Zhu	et	al.,	2013).
A	 limitation	of	 the	current	 treatment	strategy	arises	as	we	did	
not	precisely	characterize	the	kinetics	of	senescence	accumulation	
following IR nor the dynamics of senescent cell elimination following 
navitoclax	 treatment.	Exhaustive	studies	characterizing	kinetics	of	
accumulation	and	elimination	may	allow	for	an	optimized	treatment	
regime with the potential to further improve outcome.
In	the	absence	of	MI,	aged	animals	demonstrated	an	increase	in	
CM	 renewal	 following	 either	 pharmacogenetic	 or	 pharmacological	
clearance	 of	 senescence	 (Anderson	 et	 al.,	 2019;	 Lewis-McDougall	
et	al.,	2019).	However,	senescence	elimination	following	IR	did	not	
enhance	CM	regeneration	 in	 the	young	animals	used	 in	our	study.	
Following	MI,	both	the	vehicle	and	navitoclax-treated	mice	displayed	
a	similar	CM	regenerative	response,	corresponding	to	a	renewal	of	
0.47%	and	0.38%	CMs,	 respectively,	during	 the	 first	week	 follow-
ing	MI.	These	 rates	 are	 consistent	with	 those	previously	 reported	
for	 MI	 hearts	 without	 therapeutic	 intervention	 (Malliaras	 et	 al.,	
2013),	 suggesting	 that	young	animals	have	a	CM	regenerative	po-
tential	 that	 is	 not	 impeded	 by	 senescence.	 In	 contrast,	 we	 noted	
an increase in both endothelial proliferation and vessel density in 
the	hearts	of	navitoclax-treated	mice.	Based	on	our	 in vivo studies 
demonstrating	an	increase	in	peri-infarct	vascularization	in	the	nav-
itoclax-treated	 animals,	 the	observed	 association	between	post-IR	
senescence	and	the	expression	of	anti-angiogenic	cytokines	includ-
ing	 IP-10,	 together	 with	 the	 known	 anti-angiogenic	 properties	 of	
some	SASP	components	(Coppe	et	al.,	2010)	it	 is	possible	that	fol-
lowing IR senescent cells attenuate angiogenesis directly as a result 
of	the	expression	of	an	anti-angiogenic	SASP.	As	such,	the	increased	
vascularization	 post-IR	 following	 navitoclax	 treatment	 may	 occur	
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because	of	a	reduction	in	the	SASP.	However,	it	is	also	possible	that	
senescence	and	the	SASP	contribute	to	attenuated	angiogenesis	as	
a result of the bystander effect and the induction of senescence in 
the endothelial cell population reducing proliferative potential as a 
result	of	cell-cycle	arrest,	a	hypothesis	supported	by	our	in vitro con-
ditioned	media	 studies.	Additional	 in vivo	 experiments	quantifying	
senescence	specifically	in	endothelial	populations	would	be	required	
to dissect these two possible mechanisms. Regardless of the mech-
anisms	 involved,	 improved	 angiogenesis	 and	 improved	myocardial	
oxygenation	may	 also	 contribute	 to	 the	observed	 improvement	 in	
cellular	 respiration.	 In	 this	 context,	 however,	 we	 have	 previously	
demonstrated that myocardial aging and accumulated senescence is 
associated	with	mitochondrial	dysfunction	 (Anderson	et	al.,	2019).	
Therefore,	a	reduction	in	senescence	cells	with	dysfunctional	mito-
chondria,	by	navitoclax	treatment,	may	also	contribute	directly	to	a	
global increase in mitochondrial function.
In	conclusion,	these	data	suggest	a	key	role	of	myocardial	senes-
cence	signaling	downstream	of	the	initial	oxidative	stress	response	
to	reperfusion.	We	suggest	that	targeting	senescence	is	a	valid	and	
clinically feasible strategy to attenuate maladaptive remodeling and 
promote	recovery	post-IR.	Major	advantages	of	senolytic	treatment	
over	current	strategies	include	1)	targeting	senescence	which	occurs	
as	a	result	of	the	cellular	stress	associated	with	IRI	provides	an	ex-
tended	therapeutic	window;	and	2)	targeting	senescence	attenuates	
multiple	 components	 of	 the	 inflammatory	 responses	 subsequent	
to	 IR,	which	are	detrimental	 to	 recovery	 (Prabhu	&	Frangogiannis,	
2016;	Sánchez-Hernández	et	al.,	2020).	Recent	studies	have	begun	
to trial senolytics in patients suffering from pulmonary fibrosis or 
kidney	disease	(Hickson	et	al.,	2019;	Justice	et	al.,	2019),	and	if	se-
nolytics	prove	to	be	effective	and	safe,	they	could	be	transformative	
for cardiovascular medicine.
4  |  E XPERIMENTAL PROCEDURES
4.1  |  Mouse model and myocardial infarction with 
reperfusion
Male	C57BL/6	J	mice	at	3-4	months	of	age	were	used	 in	all	 stud-
ies. Intra-operative analgesia was induced by pre-treating mice with 
fentanyl/fluanisone	(0.4	ml/kg,	Hypnorm),	prior	to	anesthesia	using	
isoflurane,	which	was	maintained	using	mechanical	ventilation	fol-
lowing	 endotracheal	 intubation	 (3%	 isoflurane/97%	 oxygen,	 130-
140	stroke	rate,	stroke	volume	initially	5	ml/kg—increased	to	7.5	ml/
kg	post-thoracotomy).	At	the	fourth-intercostal	space,	left-side	thor-
acotomy	was	executed	to	allow	partial	removal	the	pericardium	and	
enable a 7-0 prolene suture to be placed around the left anterior de-
scending	artery	(LAD)	and	loosely	tied.	An	infarction	was	induced	by	
inserting	2	mm	PE-10	tubing	into	the	suture	loop	and	tightening	the	
suture knot to terminate blood flow for 60 minutes. The tubing was 
removed	 to	allow	myocardial	 reperfusion,	 the	chest	 cavity	closed,	
and	0.05	mg/kg	Vetergesic	was	provided	as	analgesia.	Naïve	mice	
(no	 surgical	 intervention)	were	 used	 as	 control.	 All	 animal	 studies	
were conducted in accordance with the Guidance on the Operation 
of	the	Animals	(Scientific	Procedures)	Act,	1986	(UK	Home	Office),	
and approved by the local ethics committee.
4.2  |  In vivo navitoclax (ABT263) treatment
Navitoclax	 was	 prepared	 in	 a	 lipid	 vehicle	 solution	 consisting	 of	
EtOH,	polyethylene	glycol	 400	and	Phosal	 50	PG	 in	 a	1:3:6	 ratio,	
respectively	 (Chang	et	al.,	2016).	Mice	were	 randomly	assigned	 to	
experimental	groups.	Navitoclax	(50	mg/kg/day	via	oral	gavage)	was	
provided	for	the	dose	timing	regimes	detailed	in	the	main	text.	When	
required,	EdU	(100	mg/kg/d)	was	provided	via	intraperitoneal	injec-
tion	(Richardson,	2016;	Richardson	et	al.,	2015).
4.3  |  Histology and Immunohistochemistry
Immunohistochemistry was performed as described previously 
(Richardson	et	al.,	2012).	10	μm sections were used for all studies. 
Primary	antibodies	used:	rat	ant-p21	(HUGO291,	Abcam	ab107099),	
goat-anti-troponin	C	 (Abcam,	ab30807),	 rabbit	anti-p16	 (Rockland,	
100-401-170)	 and	 rat	 anti-CD31	 (MEC13.3,	 BD	 Biosciences,	
550274).	 Secondary	 antibodies	 used	 were	 donkey	 anti-rat	 AF594	
(Life	 Technologies,	 A21209),	 donkey	 anti-goat	 AF	 488	 nm	 (Life	
Technologies,	A11055),	donkey	anti-rabbit	AF594	(Life	Technologies,	
R37119),	 donkey	 anti-goat	 AF488	 (Life	 Technologies,	 A11055)	
and	donkey	anti-mouse	AF647	 (A31571,	Life	Technologies).	Slides	
were	mounted	in	Vectarshield	containing	DAPI	(Sigma,	MBD0015).	
5-ethynyl-2-deoxyuridine	(EdU)	labeling	performed	with	Invitrogen	
Click-iT	EdU	Alexa	Fluor	594	Imaging	Kit	(Life	Technologies,	C10339).
4.4  |  Rockland P16 antibody specificity assessment
To	 assess	 the	 specificity	 of	 the	 rabbit	 anti-p16	 (Rockland,	 100-
401-170)	 we	 compared	 p16Ink4a	 antibody	 staining	 (Rockland,	
100-401-170)	 to	 p16Ink4a	 mRNA	 expression	 using	 RNAscopeTM 
(Mm-Cdkn2a-tv2,	447491,	ACD,	C1	probe).	Staining	was	performed	
in	the	hearts	of	transgenic	mice	which	allow	for	a	CM	specific	knock-
out of p16Ink4a	exon1α	and	control	littermates	with	wild-type	(WT)	
p16Ink4a	 expression,	 at	 5	weeks	 post-IR	 (Figure	 S3).	 The	α-Myosin	
Heavy	Chain-MerCreMer	transgenic	line	(MerCreMer)	(Sohal	et	al.,	
2001)	and	a	transgenic	mouse	in	which	exon1α of p16Ink4a is flanked 
by	loxp	sites	(Sharpless	et	al.,	2001)	(p16f/f)	were	crossed	to	generate	
MerCreMer+/−:: p16f/f,	which	when	provided	tamoxifen	excise	exon	1α 
of p16inka4 specifically the α-myosin	heavy	chain-expressing	CM	pop-
ulation	and	WT::	p16f/f littermate controls. Genotype was confirmed 
using	 the	 primers	 for	 Cre	 F-TAACCAGTGAAACAGCATTGCTG,	
Cre	 R-	 GGACATGTTCAGGGATCGCCAGGCG,	 p16Ink4a	 floxed-
GTATGCTATACGAAGTTATTAGGTACTGC.	 p16Ink4a wild-type 
GTTTTGGAGCAGCAGGGATT	 and	 p16Ink4a	 common-CTATGTCA-
GATTTGGCTAGGGAGT.	Mice	were	 treated	with	 4-OH-tamoxifen	
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(Sigma)	dissolved	in	peanut	oil	at	a	concentration	of	0.5	mg/day	(I.P)	
for	2	weeks	at	previously	described	(Malliaras	et	al.,	2013)	and	sub-
jected	to	cardiac	IR	(Figure	S3A).	Excision	of	the	p16Ink4a	exon	1α was 
verified	by	PCR,
using	 LCred	 primers,	 specific	 to	 sequences	 located	 out-
side	 the	 loxP	 sites	 that	 produce	 a	 PCR	 product	 of	 approxi-
mately 270 bp or an unamplifiable product of 3.9 kb. p16Ink4a 
LCred	 F-TACCACAGTTTGAACAGCGTGA	 and	 p16Ink4a	 LCred	
R-AACCAACTTCCTCCTTCCCC	(Figure	S3B).	Immunohistochemistry	
was	 performed	 using	 the	 rabbit	 anti-p16	 (Rockland,	 100-401-
170)	 and	 donkey	 anti-rabbit	 AF594	 (Life	 Technologies,	 R37119).	
RNAscopeTM was performed according to the manufacturer's pro-
tocol	 (RNAscopeTM	 Multiplex	 Fluorescent	 Kit	 v2	 User	 Manual,	
323100-USM,	 ACD)	 (Advanced	 Cell	 Diagnostics,	 2018).	 For	 both	
staining	techniques	sections	were	co-stained	with	trop-c	 (anti-tro-
ponin	 C,	 1:800,	 ab30870,	 Abcam)	 and	 DAPI	 (1:500,	 MBD0015,	
Sigma).	 Sections	mounted	 in	Dako	Fluorescent	Mounting	Medium	
(S3023,	Agilent)	(Figure	S3C,D).
4.5  |  Senescence-associated 
β-galactosidase staining
Cryo-embedded sections were stained using the senescence-
associated β-galactosidase	 (SA-β-Gal)	 staining	 kit	 (Cell	 Signaling	
Technology,	9860)	as	per	the	manufacturer's	 instructions	with	the	
following	modifications	 for	 tissue	 sections.	 Slides	were	 thawed	 at	
room	temperature,	fixed	using	the	provided	fixative	solution	for	15	
minutes,	and	washed	three	times	in	PBS.	The	β-galactosidase stain-
ing	solution	was	prepared	at	pH	6	and	added	to	each	slide.	Slides	
were incubated at 37°C for 24 hours. Once developed slides were 
washed	with	PBS,	dehydrated	in	95%	and	100%	ethanol	solutions,	
washed	in	Histoclear,	and	mounted	with	Histomount.
4.6  |  Real-Time PCR (qRT-PCR)
Qiagen	RNA	extraction	kit	was	used	for	RNA	isolation.	First-strand	
cDNA	synthesis	kit	(Thermo	Fisher	Scientific,	Waltham,	MA,	US)	was	
used	for	cDNA	synthesis.	Real-time	PCR	was	performed	in	a	7500	
Fast	Real-Time	PCR	System	using	Taman	probes	(Life	Technologies	
Ltd,	UK)	GAPDH	 (Mm99999915_g1),	 p21	 (Rasa3)	 (Mm00436272_
m1)	and	p16	(Cdkn2a)	(Mm00494449_m1).	Data	presented	normal-
ized	to	GAPDH.
4.7  |  Immuno-FISH
Telomere-associated	DNA	damage	foci	(TAF)	were	detected	by	per-
forming	Immuno-FISH,	as	previously	described	(Passos	et	al.,	2007),	
on	cryo-embedded	heart	sections.	Briefly,	sections	that	were	labeled	
with rabbit monoclonal anti-γH2Ax	(20E3,	Cell	Signaling	Technology,	
9718)	 and	 following	 secondary	 labeling	 with	 goat-anti-rabbit	 IgG	
biotinylated	(VectorLab,	PK-6101),	sections	were	fixed	with	metha-
nol:	acetic	acid	 (3:1),	dehydrated	and	 incubated	with	PNA	hybridi-
zation	mix	with	5%	blocking	 reagent	 (Roche)	 containing	2.5	μg/ml 
Cy3-labeled	telomere-specific	(CCCTAA)	peptide	nucleic	acid	probe	
(Panagene).
4.8  |  Microscopy, image analysis, and 
quantification
All	 images	were	 acquired	 using	Axio	 Imager	 (Zeiss)	 and	 analyzed	
using	ZEN	2.3	(Zeiss).	All	quantifications	were	performed	blinded	
to	 treatment	 and	 genotype	 using	 digital	 image	 analysis	 (ImageJ;	
U.S.	 National	 Institutes	 of	 Health;	 http://rsbweb.nih.gov/ij/).	
Quantification	of	 p16,	 p21,	 EdU	was	performed	 as	we	described	
previously	 (Anderson	et	 al.,	 2019)	except	 that	quantification	was	
restricted	to	the	peri-infarct	region;	defined	as	the	region	proximal	
to	 the	 infarct	 (Figure	S1A,	 red	 region).	A	minimum	of	20	 images/
heart over 5 individual sections were taken within this peri-infarct 
area	(total	approx.	6000	cells	analyzed	per	heart).	For	each	image,	
the	total	number	of	CMs	(identified	by	trop-c	expression)	and	the	
number	of	CMs	expressing	the	protein	of	interest	were	quantified,	
allowing	the	percentage	CM	expressing	each	protein	to	be	calcu-
lated.	Similarly,	the	number	of	interstitial	cells	(identified	as	DAPI+ 
trop-c−)	expressing	the	protein	of	interest	was	quantified	allowing	
the	percentage	expression	to	be	calculated.	For	CM	EdU	quantifi-
cation,	WGA	was	also	used	 to	allow	the	 identification	of	 individ-
ual	CMs.	For	endothelial	EdU	quantification,	 the	 total	number	of	
CD31+	 endothelial	 cells	which	had	 incorporated	EdU	was	quanti-
fied	 in	 each	 image.	CM	hypertrophy	was	quantified	 as	described	
previously	 (Correia-Melo	 et	 al.,	 2019),	 following	 staining	 with	
the	 membrane	 marker	 wheat	 germ	 agglutinin	 (WGA)	 (W32466,	
Invitrogen,	UK).
4.9  |  Magnetic resonance imaging and analysis
Magnetic	resonance	 images	were	acquired	using	a	horizontal	bore	
7.0	T	Varian	microimaging	system	(Varian	Inc.,	Palo	Alto,	CA,	USA)	
equipped	with	a	12-cm	microimaging	gradient	insert	(40	gauss/cm)	
and	analyzed	as	described	previously	(Redgrave	et	al.,	2017).
4.10  |  Liquid Chromatography Mass Spectrometry 
(LC-MS/MS) with SWATH acquisition (Sequential 
Windowed Acquisition of All Theoretical Fragment 
Ion Mass Spectra)
4.10.1  |  Left ventricular sample preparation
At	the	time-points	detailed	in	the	results	section,	hearts	were	col-
lected,	and	the	 left	ventricle	 (LV)	was	dissected	apical	 to	 the	su-
ture	and	placed	in	RIPA	buffer	(R0278,	Sigma)	containing	protease	
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inhibitors.	Tissue	was	homogenized	and	proteins	precipitated	with	
acetone.	Protein	was	dissolved	in	8	M	urea,	10	mM	HEPES	at	pH	
8.0.	200	µg	of	protein	was	reduced	with	30	mM	DTT	at	30°C	for	
30	 minutes	 followed	 by	 alkylation	 with	 10	 mM	 Iodoacetamide.	
Urea	 molarity	 was	 reduced	 to	 1.5	 M	 prior	 to	 trypsin	 digestion	
(Worthington,	TPCK	 treated)	at	a	 ratio	of	20:1	 (protein:	 trypsin).	
The	 digestion	 was	 stopped	 with	 trifluroacetic	 acid	 (TFA)	 and	
proteins	purified	with	 a	 self-packed	C18	 stage	 (Rappsilber	 et	 al.,	
2007).	Peptides	were	eluted,	dissolved	in	3%	acetonitrile	with	1%	
TFA,	and	sonicated.
4.11  |  Nano-LC-MS/MS
Analysis	was	performed	with	an	AB-Sciex	6600-Tripletof	operating	
in	 SWATH	mode.	 Protein	 digests	were	 injected	 into	 a	mass	 spec-
trometer	 through	 an	 UltiMate	 3000	 RSLCnano	 system.	 Samples	
were loaded onto a 300 μm	 x	 5	 mm	 C18	 PepMap	 C18	 trap	 car-
tridge	in	0.1%	formic	acid	and	then	separated	at	300	nl/min	using	a	
95	min	nonlinear	gradient	(3-30%ACN:87	min;	30-40%:10	min;	40-
90%:5	min)	using	a	75	μm	x	25	cm	C18	column	(ReproSil-Pur	Basic-
C18-HD,	3	µm,	Dr.	Maisch	GmbH).	The	eluent	was	directed	 to	an	
Ab-Sciex	TripleTOF	6600	mass	spectrometer	through	the	AB-Sciex	
Nano-Spray	 3	 source,	 fitted	 with	 a	 New	 Objective	 FS360-20-10	
emitter.	SWATH	acquisition	was	performed	in	a	mass	range	of	400-
800	m/z,	with	75	variable	SWATH	bins	and	accumulation	time	of	40	
milliseconds.	The	number	of	SWATH	bins	was	estimated	based	on	a	
pilot	DDA	run	of	a	random	sample	using	SWATH	variable	window	
calculator	ver.1.1	(AB	Sciex).
All	the	raw	data	with	the	associated	search	results	were	depos-
ited	 in	 a	 publicly	 accessible	 repository	 (https://massi	ve.ucsd.edu/,	
MSV000085040)	(Wang	et	al.,	2018).
4.12  |  Data analysis
The	SWATH	files	were	processed	in	PeakView	2.1	(AB	Sciex)	with	
the	SWATH	MSMSall	micro	 app	 (top	1000	peptides/protein,	 top	
5	transitions/peptide,	confidence	threshold:	95%,	FDR	threshold:	
1%,	modified	peptides	excluded,	extraction	window:	10	min,	XIC	
width:	 10	 ppm).	 The	 mouse	 heart	 spectral	 library	 was	 obtained	
from	 ProteomeXchange	 (Vizcaíno	 et	 al.,	 2014)	 (PXD017795,	
MSV000085036)	and	pre-aligned	to	a	randomly	selected	SWATH	
file,	 as	 described	 (Palmowski	 et	 al.,	 2019).	 The	 results	 were	 ex-
ported,	 via	MarkerView	1.2.1	 (AB	Sciex),	 as	 tab-separated	ASCII	
files and processed using the Perseus software framework 
(Tyanova	et	al.,	2016).	Protein	peak	areas	were	transformed	to	log	
scale,	 followed	 by	median	 subtraction	 (sample	median	 was	 sub-
tracted	to	account	for	loading	differences),	and	the	values	derived	
from technical replicates were averaged. Individual proteins had to 
be	quantifiable	in	all	samples	to	meet	the	criteria	for	further	analy-
sis. T-test was applied to identify proteins that differed in relative 
abundance	between	experimental	groups	and	permutation-based	
false discovery rate was estimated to account for multiple com-
parisons.	Protein	groups,	following	the	relative	abundance	profiles	
of	interest,	were	then	extracted.	The	log2	peak	areas	were	first	z-
scored for each protein and the reference profile was defined. For 
each	protein,	a	sum	of	squared	differences	 (differences	between	
measured	values	and	the	reference)	was	calculated	as	a	measure	of	
distance from the reference. The resulting values were then used 
for	 permutation-based	 FDR	 calculation	 (R-Script	 file	 supplemen-
tary	 data)	 to	 allow	 confident	 identification	 of	 proteins	 that	 fol-
lowed	a	predefined	abundance	profile.	Association	with	particular	
subcellular	 compartments,	 biological	 functions	or	 pathways,	was	
assessed for molecules differentially abundant between condi-
tions	 and/or	 sharing	 the	 same	 abundance	 profile,	 using	 STRING	
v11.0	 (Szklarczyk	et	al.,	2019),	 followed	by	manual	 interrogation.	
Statistical	 background	 for	 pathway/enrichment	 analysis	 was	 re-
stricted	only	to	proteins	detected	in	the	analyzed	samples.
4.13  |  Scar size quantification
Masson's	 trichrome	 staining	 was	 performed	 in	 order	 to	 visualize	
scar	tissue	(Bogatyryov	et	al.,	2013).	Hearts	were	sectioned	into	5	
sets	of	slides,	10	slides	per	set	and	stained	with	Masson's	trichrome.	
Each	set	of	slides	was	imaged	and	analyzed	using	the	Leica	Digital	
Image	Hub.	The	LV	area	was	calculated	by	measuring	the	epicardial	
area and subtracting the endocardial area. The infarct area was then 
measured	and	the	percentage	of	LV	that	is	infarct	calculated	to	ana-
lyze	scar	size.
4.14  |  Cell culture
Cell culture work has been performed using human embryonic 
lung	 MRC5	 fibroblasts	 acquired	 from	 European	 Collection	 of	
Authenticated	Cell	Cultures	(05072101),	Salisbury,	UK,	and	mouse	
cardiac	endothelial	cells	from	Cedarlane	(CLU510-P).
4.15  |  Statistical analysis
All	analyses	were	performed	in	a	blinded	manner.	All	analyses	were	
performed	using	GraphPad	Prism	8.0.	Data	were	first	tested	for	nor-
mality.	Parametric	data	were	analyzed	using	a	2-tailed	t-test	or	one-
way	ANOVA,	as	appropriate.
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